Capecitabine (CAS 154361-50-9) is a high-purity anticancer API, a potent oral prodrug designed for targeted tumor cell inhibition. With a unique prodrug structure, it is selectively activated into fluorouracil (5-FU) in tumor tissues, effectively interfering with DNA synthesis and suppressing tumor cell proliferation.
Produced under strict GMP standards, this API ensures consistent purity, potency, and stability, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for breast cancer, colorectal cancer, and gastric cancer treatment, catering to the needs of pharmaceutical manufacturers and research institutions focusing on anticancer pharmaceutical R&D.
Its tumor-specific activation mechanism minimizes systemic toxicity in formulated products, balancing high efficacy with favorable safety profiles. As a trusted raw material for oral anticancer drugs, Capecitabine delivers reliable performance for both clinical research and large-scale pharmaceutical production, supporting the development of effective cancer treatment solutions.
